Pfizer Signs a License and Supply Agreement with ImaginAb for CD8 ImmunoPET Technology

 Pfizer Signs a License and Supply Agreement with ImaginAb for CD8 ImmunoPET Technology

Pfizer Signs a License and Supply Agreement with ImaginAb for CD8 ImmunoPET Technology

Shots:

  • ImaginAb to receive license fees and payments for manufacturing and other support and will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology clinical trials
  • ImaginAb will provide technical, clinical & regulatory support to Pfizer
  • The collaboration follows the pre-competitive alliance b/w ImaginAb, Pfizer and other global companies focusing on the development of 89Zr CD8 ImmunoPET technology, signed in Oct 14, 2019

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post